ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 772

Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

John Conklin1, Basil Jones2, Tyler O'Malley3, Duncan Poling4, JoAnne Ligayon5, Leilani Wolover6, Ying Qu7, Claudia Ibarra8, Puja Chitkara9 and Thierry Dervieux3, 11261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 2Exagen Diagnostics, Vista, CA, 3Research and Development, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics Inc., Vista, CA, 5Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, 6Research and Development, Exagen Diagnostics, Inc., Vista, CA, 7Exagen Diagnostic Inc, Vista, CA, 8Clinical Laboratory, Exagen Diagnostics, Vista, CA, 9Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, complement, flow cytometry and laboratory tests, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed that the determination of C4d fragment, the activation product of C4 in its soluble or cell-bound form to erythrocytes (EC4d), or B-lymphocytes (BC4d) could help diagnose SLE. However, one of the challenges in determining complement activation is the stability of these products post-phlebotomy. Our objective was to quantify the effects of time and temperature on soluble and cell bound C4d.

Methods: Venous blood was collected in EDTA-containing tubes from 12 subjects with SLE (67% females, mean age 39 years) and 15 normal healthy volunteers (NHV) (48% females, mean age 38 years). All subjects enrolled provided informed consent. Following venipuncture, the blood was equally distributed into polypropylene tubes and stored at either 4°C or ambient room temperature (22°C) for up to two days post phlebotomy. These conditions mimic the transportation condition of a typical specimen. Starting on the day of collection (day 0), and the following two days, plasma was isolated from the stored whole blood. Soluble plasma C4d concentration was determined using immunoassays (MicroVue C4d EIA, Quidel). EC4d and BC4d were determined from stored whole blood using flow cytometry and reported as net mean fluorescence intensity (MFI). The relationship between the change in the markers from baseline as a function of time and temperature was estimated with linear mixed-effect models.

Results: Soluble C4d (baseline levels 0.8±0.3 µg/ml) was significantly affected by both time (increase of 1.1 ± 0.1 µg/ml per day) and storage conditions (increase of 0.7 ± 0.1 µg/ml at ambient temperature versus 4°C) (Table 1). After two days storage at ambient temperature, soluble C4d levels increased by more than 2 fold compared to baseline plasma concentrations. By comparison, EC4d and BC4d levels were not significantly impacted by time and storage at ambient temperature. EC4d and BC4d levels were 15.9 and 62.5 net MFI after two days storage at room temperature, respectively, by comparison to 15.8 and 65.5 net MFI at day 0. In this small population of subjects, elevated CBCAPS (EC4d>14 net MFI or BC4d>60 net MFI) were 73% sensitive for SLE and 100% specific (vs. NHV).

Conclusion: Our data suggest soluble C4d is unstable during transportation and delivery of specimen to the clinical laboratory. However, cell-bound C4d is a stable measure of complement activation and could be used as complement activation biomarker in multi-centered studies.

Table 1: Estimates for biomarker change as a function of storage days and temperature. Days represent the per-day change of each marker at 4°C. Ambient temperature represents the overall increase for each marker at that temperature.

*The predicted soluble C4d concentration at 2 days storage at ambient temperature is 0.8 + 1.1×[2] + 0.7×[1] = 3.1 µg/mL

Marker (Units) Day0 Levels (CI95%) Days Ambient Temperature (22°C)
Soluble C4d (µg/mL) 0.8 ± 0.3 1.1 ± 0.1 0.7 ± 0.1
EC4d (Net MFI) 15.8 ± 2.8 -0.2 ± 0.2 0.1 ± 0.3
BC4d (Net MFI) 65.5 ± 12.8 -2.0 ± 1.3 1.1 ± 2.1

Disclosure: J. Conklin, Exagen, 3; B. Jones, Exagen Diagnostics Inc., 3; T. O'Malley, Exagen, 3; D. Poling, Exagen Diagnostics Inc., 3; J. Ligayon, Exagen Diagnostics Inc., 3; L. Wolover, Exagen Diagnostics Inc., 3; Y. Qu, Exagen Diagnostics Inc., 3; C. Ibarra, Exagen, 3; P. Chitkara, Exagen Diagnostics, 6; T. Dervieux, Exagen, 3.

To cite this abstract in AMA style:

Conklin J, Jones B, O'Malley T, Poling D, Ligayon J, Wolover L, Qu Y, Ibarra C, Chitkara P, Dervieux T. Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/post-phlebotomy-stability-of-soluble-and-cellular-forms-of-complement-activation-implications-in-sle-diagnostic-assays/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-phlebotomy-stability-of-soluble-and-cellular-forms-of-complement-activation-implications-in-sle-diagnostic-assays/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology